Updates are available Correction dated 2025-05-12
Click to view Correction: https://doi.org/10.1038/s41419-025-07631-y
-
Authors
Dmello, Rhynelle S.
Palmieri, Michelle
Thilakasiri, Pathum S.
Doughty, Larissa
Nero, Tracy L. https://orcid.org/0000-0002-3393-1843
Poh, Ashleigh R. https://orcid.org/0000-0001-8375-4753
To, Sarah Q.
Lee, Erinna F.
Douglas Fairlie, W. https://orcid.org/0000-0002-2498-1160
Mielke, Lisa https://orcid.org/0000-0002-9522-9320
Parker, Michael W. https://orcid.org/0000-0002-3101-1138
Poon, Ivan K. H. https://orcid.org/0000-0002-9119-7173
Batlle, Eduard https://orcid.org/0000-0003-2422-0326
Ernst, Matthias https://orcid.org/0000-0002-6399-1177
Chand, Ashwini L. https://orcid.org/0000-0002-1245-729X
-
Funding
Funding for this research was provided by:
Victorian Cancer Agency (19014)
Cancer Council Victoria (1143036)
Department of Health | National Health and Medical Research Council (1194263)
Department of Health | National Health and Medical Research Council (1166447)
AARP Foundation (11666447)
Victorian Cancer Agency
- License Information
-
More Information
Article History
Received: 17 January 2023
Revised: 8 March 2024
Accepted: 22 March 2024
First Online: 10 April 2024
Change Date: 22 April 2025
Change Type: Update
Change Details: "The original online version of this article was revised: "In this article, the affiliation for author Eduard Batlle is incomplete. The complete affiliation is: 6.Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain. 7.Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain. 8.Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.
Change Date: 12 May 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41419-025-07631-y
Competing interests
: M.E is a shareholder and adviser for Lassen Therapeutics for the development of IL-11 signalling antagonists.
